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Abstract The human μ-opioid receptor and a mutant form, |iS/ 
T[i3+Cter]A, in which all Ser and Thr residues from the third 
cytoplasmic loop and C-terminal domain were changed to Ala, 
were studied after expression in CHO-K1 cells. Although the 
mutant receptors had similar affinities for agonists and ECr,n 
values for inhibition of adenylyl cyclase as compared to wild-type 
receptors, the Emax were almost 2-fold decreased, suggesting a 
role of the mutated residues in G-protein coupling. After chronic 
morphine or etorphine, the EC50 values of the agonists were 
about 5-fold increased at both receptors but the Emax values were 
not altered; upon agonist withdrawal forskolin-stimulated cAMP 
levels were increased to almost 200% of control levels. 
Sequestration and rapid down-regulation of the μ-opioid receptor 
were induced by DAGO and etorphine but not morphine. In 
contrast, the μ8/Τ[ί3+ΟεΓ]Α receptor was not sequestered and 
was up-regulated (150-380%) after treatment with agonists. The 
results indicate that the Ser and Thr residues in the third 
cytoplasmic loop and C-terminus of the μ-opioid receptor are not 
involved in the limited desensitization or in the adenylyl cyclase 
superactivation promoted by agonists but that their integrity and/ 
or their phosphorylation is required in the intricate and 
coordinately regulated pathways involved in receptor signaling 
and trafficking. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Three main classes of integral membrane receptors, termed 
μ, δ and κ, mediate the pharmacological actions of opioids by 
coupling to regulatory G-proteins and modulating K+ and 
Ca2+ channels, adenylyl cyclase, and phospholipase C activ-
ities. Morphine and alkaloid derivatives acting through μ re-
ceptors remain the most powerful drugs for the treatment of 
pain but their administration is limited by undesirable side 
effects, including tolerance and dependence. Tolerance is char-
acterized by a decreased responsiveness to opioids upon con-
tinuous or repeated exposure to the drugs. Dependence is ex-
pressed upon withdrawal of the opioid, or administration of 
an antagonist, by physiological symptoms often opposite to 
the acute effects of the drug. In the long term, tolerance and 
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dependence involve profound modifications of neuronal activ-
ity which are certainly triggered by adaptive changes of opioid 
receptor properties. 
For several G-protein-coupled receptors exemplified by the 
ß-adrenergic receptors, attenuated cellular responsiveness to 
agonists, also known as desensitization, has been correlated 
to alterations of receptor coupling to G-proteins and to inter-
nalization and down-regulation of receptors. Phosphorylation 
by various kinases (PKA, PKC and GRK) of serine and 
threonine residues located in the third cytoplasmic loop and 
carboxy-terminal tail of the receptors is believed to be at the 
basis of the desensitization process which also involves intra-
cellular effectors such as ß-arrestins and other regulators of G-
proteins signaling [1]. 
Early studies using whole animals and model cell lines have 
failed to reveal consistent links between modifications of 
opioid responsiveness and receptor properties. The recent 
cloning of opioid receptor cDNAs has made it possible to 
better explore the possible adaptive changes of receptor func-
tion after sustained exposure to agonists. It has thus been 
suggested that agonist-stimulated phosphorylation of the μ-
opioid receptor could lead to its constitutive activation rather 
than to desensitization and that this would be responsible for 
the development of narcotic tolerance and dependence [2,3]. 
In contrast, phosphorylation of δ- and κ-opioid receptors has 
been suggested to induce desensitization of both receptors 
[4,5]. 
In the present study, we expressed in CHO-K1 cells the 
wild-type μ-opioid receptor and a mutant form termed μ8/ 
T[i3+Cter]A where serine and threonine residues in the third 
intracellular loop and carboxy-terminal tail have been re-
placed by alanine, to investigate the possible implication of 
these regions in the adaptive processes of μ-opioid receptor 
signaling. 
2. Materials and methods 
2.1. Construction and expression of wild-type and mutant μ-opioid 
receptors 
Unique restriction sites were introduced by silent oligonucleotide-
directed mutagenesis into the human μ-opioid receptor cDNA [6] to 
facilitate the construction of mutant receptors. The sequences encod-
ing L261-K262 and T281-R282 in the third intracellular loop (i3), and 
that encoding E393-A397 in the C-terminus of the receptor were re-
spectively modified to create Aflil, Mlul and Sfil restriction sites. The 
μ8/Τ[ί3+0:εΓ]Α mutant in which all Ser and Thr residues from i3 (3 
Ser and 1 Thr) and the carboxy-terminal tail (4 Ser and 7 Thr) were 
substituted by Ala was obtained by replacing the Aflll to Mlul, 
PpulOl to EcoRl and EcoRl to Sfil fragments with synthetic oligo-
nucleotides containing the desired mutations and restrictions sites 
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convenient for screening purposes. Constructs were verified by sense 
and anti-sense sequencing throughout the modified regions. 
The coding regions of receptors were subcloned into the pRc/CMV 
expression vector (Invitrogen, San Diego, CA, USA) and transfected 
into CHO-K1 cells (CCL-61, ATCC, Rockville, MD) by the calcium 
phosphate procedure. G418-resistant clones (400 μg/ml) were individ-
ually grown and subcloned by limiting dilution before screening for μ 
receptor expression using binding of 1 nM [3H]diprenorphine to whole 
cells. 
2.2. Receptor binding assays 
Membrane preparation and receptor binding assays were performed 
as described [6]. For saturation experiments, 10-100 μg membrane 
proteins were incubated in 500 μΐ of binding buffer with 13 concen-
trations of [3H]diprenorphine ranging from 0.1 to 3 nM. Inhibition of 
[3H]diprenorphine (0.4 nM) binding was performed with concentra-
tions of competitors ranging from 10 -11 to 10~5 M. Non-specific 
binding was determined in the presence of 1 μΜ diprenorphine. Fol-
lowing a 1 h incubation period at 25°C, free ligand was removed by 
filtration onto Whatman GF/B filters and bound radioactivity was 
measured. Data were analyzed with the Inplot 4 program (Graphpad 
Software Inc., San Diego, CA, USA). Results are presented as the 
mean ± S.E.M. of three independent experiments performed in dupli-
cate. 
Down-regulation and sequestration of μ-opioid receptors were 
studied on whole cells plated into a 24-well dishes (2X105 cells/well) 
and allowed to recover overnight. Fresh medium alone or containing 
agonists (10 μΜ DAGO, 10 μΜ morphine, or 1 μΜ etorphine) was 
then added. Ligands were removed by sequential 30 min washes at 
4°C: four washes in Ham's F12 supplemented with 10% fetal bovine 
serum and two washes in PBS containing 0.2% bovine serum albumin. 
Cells were then incubated for 2 h on ice in the latter buffer supple-
mented with 2.5 nM [3H]diprenorphine. After three rapid washes with 
PBS/BSA 0.2%, cells were lysed using a solution of 0.2 N NaOH 
and 0.5% SDS, and lysates were harvested and counted. Intracellular 
binding sites and non-specific binding were defined as occurring 
in the presence of 10 μΜ DAGO and 1 μΜ diprenorphine, respec-
tively. 
2.3. cAMP accumulation assays 
Cells were seeded in 12-well culture plates (105 cells/well) and al-
lowed to attach for 24 h. Cells were then incubated four 4 h at 37°C 
with 0.6 μΟΛνεΙΙ of [3H]adenine (23 Ci/mmol, Amersham). Adenylyl 
cyclase activity was stimulated by the addition of 10 μΜ forskolin 
(FS) in 0.25 ml HEPES buffered Krebs-Ringer saline (KRH) contain-
ing phosphodiesterase inhibitors (0.1 mM IBMX and 0.1 mM Ro 20-
1724) in the presence or absence of varying concentrations of agonists 
ranging from 10~H to 10~6 M. After incubation for 10 min at 37°C, 
25 μΐ of 2.2 N HC1 was added and cAMP levels were measured [7], 
For chronic treatments, opioid agonists were added to cultures for 4 h 
together with [3H]adenine. Four rapid washes with 0.5 ml of KRH 
were performed to achieve withdrawal of opioid agonists and cAMP 
accumulation assays were performed as above. For efficient removal 
of the slowly dissociating etorphine, cells were rinsed twice with KRH 
buffer containing 100 μΜ naloxone, incubated for 10 min at 37°C in 
the same medium and rinsed four times with KRH alone. Data are 
expressed as the percentage of FS-stimulated cAMP accumulation in 
untreated cells. 
3. Results 
3.1. Pharmacological properties of the μ and ßSIT[i3+Cter]A 
opioid receptors 
Saturation binding experiments revealed that both the μ 
and the μ8/Τ[ί3+0ΐβΓ]Α opioid receptors expressed in CHO-
Kl cells had comparable affinities for [3H]diprenorphine 
(0.10 ±0.01 nM vs. 0.29 ±0.02 nM), which agreed with those 
measured in mammalian tissues or transfected cells. Ex-
pression levels were 3.5 ±0.5 and 0.6 ±0.1 pmol/mg of mem-
brane proteins for the wild-type and mutant receptors, respec-
tively. 
Competition of [3H]diprenorphine binding by DAGO, mor-
phine, and etorphine showed that affinities of agonists were 
identical for μ and μ8/Τ[ί3+ΟΐεΓ]Α receptors when inhibition 
curves were fitted to a one-site model (wild-type vs. mutant; 
1.310.2 nM vs. 1.710.2 nM for DAGO and 3.3 + 0.3 nM vs. 
5.310.5 nM for morphine). For the μ receptor however, the 
DAGO and morphine curves were best fitted to a two-site 
model («mn = 0.6210.03 and 0.59 + 0.03, respectively). In the 
presence of 100 μΜ Gpp(NH)p the ratio of high affinity sites 
decreased from 50 to 30% for DAGO and from 43% to un-
detectable for morphine (Table 1). For these agonists, the 
mutant receptor presented a single affinity state similar to 
the low affinity state of the wild-type receptor, which was 
not influenced by the presence of Gpp(NH)p. Surprisingly, 
both proteins presented a single and comparable affinity for 
etorphine. 
For μ and μ8/Τ[ί3+ΟβΓ]Α receptors, modulation by ago-
nists of FS-stimulated cAMP accumulation produced dose-
dependent inhibition curves (not shown). The rank order of 
potency of agonists (etorphine»DAGO > morphine) and 
EC50 values were similar for the two receptors but maximal 
inhibition levels were decreased for the μ8/Τ[ί3+ΟίεΓ]Α mu-
tant (Table 2). 
Table 1 
Inhibition constants of agonist binding to μ and μ8/Τ[ί3+ΟβΓ]Α opioid receptors expressed in CHO-K1 cells 
Receptor 
μ 
μ8/Τ[ί3+»βΓ]Α 
Agonist 
DAGO 
+Gpp(NH)pa 
Morphine 
+Gpp(NH)p 
Etorphine 
DAGO 
+Gpp(NH)p 
Morphine 
+Gpp(NH)p 
Etorphine 
K, (nM) 
^iH 
0.26 ± 
0.20 ± 
0.40 ± 
ND b 
0.05 
0.01 
0.05 
0.23 ±0.07 
1.7 ±0.2 
2.3 ±0.2 
5.3 ±0.5 
6.4 ±1.8 
0.36 ±0.07 
KiL 
7.0 ±0.3 
5.7 ±0.2 
10.4 ±0.5 
7.1 ±0.3 
Rn (%) 
50 ±3 
29 ±1 
43 ±1 
ND 
Membranes from CHO cells were incubated with 0.4 nM [3H]diprenorphine in the presence of varying concentrations of the indicated agonists. .Km 
and Ä;L refer to high and low affinity agonist binding sites of competition curves fitted to a two-site model. Ru represents the percentage of sites in 
the high affinity state for agonists. Results are the mean ± S.E.M. of three or four independent experiments performed in duplicate. 
"Binding in the presence of 100 μΜ Gpp(NH)p. 
bND, not detectable. 
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Table 2 
Inhibition of forskolin-stimulated cAMP accumulation in control and agonist-exposed CHO cells expressing the μ and μ8/Τ[ί3+ΟβΓ]Α opioid 
receptors 
Receptor 
μ 
μ8/Τ[ί3+αβΓ]Α 
Agonist 
DAGO 
Morphine 
Etorphine 
Etorphineb 
DAGO 
Morphine 
Etorphine 
Etorphineb 
Control 
EC50 
(nM) 
11 ±1 
65 ±4 
0.31 ±0.01 
0.66 ±0.11 
14 ±2 
48 ±4 
1.3 ±0.4 
4.2 ±2.0 
p 
(%) 
84±3 
76±4 
93 ±1 
92±3 
53 ± 3 
48±6 
60±5 
61±4 
Agonist exposure (4 h) 
EC50 
(nM) 
25 ±5 
244 ± 24** 
ND a 
4.7 ±1.0* 
23 ±3 
200 ±32* 
ND a 
6.8 ±2.3 
-^max 
(%) 
86±2 
81 ±3 
11 ±5 
87 ±5 
42 ±1 
59 ±7 
3 ± 6 
62 ±3 
Cells were cultured for 4 h in the absence of agonists (control) or exposed to 10 μΜ DAGO, 10 μΜ morphine or 1 μΜ etorphine. cAMP assays 
were then performed in the presence of 10 μΜ FS and varying concentrations of the corresponding agonist. The resulting curves were used to 
calculate agonist half-effective concentrations (EC50) and maximal inhibition levels of FS-stimulated cAMP accumulation (£max). Data represent 
the mean ± S.E.M. of 3-6 independent experiments performed in triplicate or quadruplicate. 
aND, not determined. 
bValues obtained after washing cells in the presence of 10~4 M naloxone (see text for details). 
*P<0.05, **P<0.01, compared to untreated cells. 
3.2. Effects on adenylyl cyclase activity of chronic exposure of 
μ and ßSIT[i3+Cter]A receptors to agonists 
Chronic exposure (4 h) to DAGO (10 μΜ) or morphine (10 
μΜ) of μ and μ8/Τ[ί3+ΟεΓ]Α receptors followed by restim-
ulation by the same agonist yielded Emax values for inhibition 
of FS-stimulated adenylyl cyclase which were not affected as 
compared to untreated cells (Table 2). A slight decrease (4-
fold) of morphine EC50 values was, however, observed for 
both receptors following morphine treatment. No modifica-
tion of DAGO EC50 occurred after DAGO treatment. 
Chronic activation by DAGO or morphine of wild-type 
followed by withdrawal of agonists led, as observed in other 
systems [8,9], to an increased (180% of control cells) FS-stimu-
lated cAMP production (Fig. 1). A smaller but significant 
adenylyl cyclase overshoot was obtained with the μ8/Τ[ί3+^ 
ter]A receptor exposed to DAGO (125%) or to morphine 
(145%). Inhibition of cAMP accumulation upon acute or 
chronic morphine, and adenylyl cyclase superactivation after 
sustained exposure to morphine were totally suppressed by 
pertussis toxin treatment (not shown), indicating that Gi/Go 
proteins were involved in these processes [9]. 
As in HEK-293 cells [10], responsiveness to etorphine of 
CHO-K1 cells expressing the μ-opioid receptor was abolished 
after a 4 h pretreatment with 1 μΜ etorphine; the same effect 
was obtained for the μ8/Τ[ί3+ΟεΓ]Α receptor (Table 2). Nei-
ther of the two receptors displayed the adenylyl cyclase over-
shoot seen with DAGO and morphine (Fig. 1). On the con-
trary, the FS-induced cAMP accumulation was reduced to 
about 50% of that of untreated cells. However, upon addition 
of 10 μΜ naloxone together with FS in the adenylyl cyclase 
assay, cAMP concentrations returned to the level of untreated 
cells (Fig. 1). Such an effect of naloxone may reflect continu-
ous activation of receptors by etorphine which indeed slowly 
dissociates from brain opioid binding sites [11]. 
Since naloxone may accelerate the dissociation of etorphine 
from opioid receptors [11], this antagonist was included dur-
ing the washing procedure (see Section 2) to verify this pos-
sibility. Under these conditions, -Emax values of etorphine at 
Table 3 
Regulation of cellular density and plasma membrane expression of μ and μ8/Τ[ί3+ΟβΓ]Α opioid receptors 
30 min exposure 
none 
DAGO 
Morphine 
Etorphine 
24 h exposure 
none 
DAGO 
Morphine 
Etorphine 
[3H]DPN binding site 
μ 
total 
(% of control) 
100 
5 8 ± 4 * * 
94±6 
75 ±5** 
100 
55 + 3** 
90±5 
42 + 3** 
DAGO inaccessible 
(% of total) 
20 ±1 
31 ± 1 * * 
12±2** 
58 ± 11* 
18±2 
14±1 
12±2 
33 ±7 
μ8/Τ[ί3+αβΓ]Α 
total 
(% of control) 
100 
103 ±9 
105 ±6 
106 ±10 
100 
155 ±10** 
376± 15** 
208 ±19** 
DAGO inaccessible 
(% of total) 
23 ±3 
17 + 1* 
11 ±3** 
21 ±3 
18±6 
10±2 
4 ± 1 
14±3 
Binding of [3H]diprenorphine was performed on intact cells exposed as indicated to 10 μΜ DAGO, 10 μΜ morphine or 1 μΜ etorphine. Total 
binding was defined as that displaceable by 1 μΜ diprenorphine and is expressed as the percentage of that occurring in untreated cells. DAGO 
inaccessible sites were those remaining in the presence of 10 μΜ DAGO. Results are the mean ± S.E.M. of 3-6 independent experiments performed 
in duplicate. 
*P<0.05, **P<0.01, compared to untreated cells. 
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Fig. 1. Adenylyl cyclase superactivation following chronic exposure to agonists of CHO cells expressing μ or μ8/Τ[ί3+ΟβΓ]Α opioid receptors. 
Cells were cultured for 4 h in the absence or presence of 10 μΜ DAGO, or 10 μΜ morphine, or 1 μΜ etorphine and rinsed four times with 
KRH. Results represent the percentage, as compared to control cells (white bars), of FS-stimulated cAMP accumulation in agonist-treated cells 
(hatched bars). Results obtained after chronic etorphine when 10 μΜ naloxone was added with FS in the cAMP assay are shown (bold-hatched 
bars). Since the lack of rebound effect after etorphine treatment may reflect receptor occupancy by etorphine, untreated cells (gray bars) or cells 
exposed to etorphine (cross-hatched bars) were washed in the presence of naloxone (see text for details) before measurement of FS-stimulated 
cAMP production. 
each receptor were not altered by etorphine treatment (Table 
2). A diminution of etorphine EC50 value was, however, found 
for the wild-type μ receptor and to a lesser extent for the \iSI 
T[i3+Cter]A mutant. Control cells expressing μ or μ8/Τ[ι3+0 
ter]A receptors washed under these conditions displayed a 
50% decrease in FS-stimulated cAMP levels (Fig. 1) which 
has also been observed in SH-SY-5Y cells [2]. Compared to 
these control cells, a significant superactivation of adenylyl 
cyclase (150-160%) was unmasked for the μ receptor but 
did not occur consistently for the μδ/Τ[ί3+ΟεΓ]Α mutant 
(Fig. 1). 
3.3. Effects of chronic exposure to agonists of μ and 
ßSIT[i3+Cter]A receptors on receptor density and 
sequestration 
After exposure to agonists, both surface and intracellular 
receptors were labelled using saturating doses (2.5 nM) of the 
lipophilic ligand [3H]diprenorphine. Sequestered binding sites 
were defined as those occurring in the presence of 10 μΜ 
DAGO, a polar peptide which only blocked cell surface re-
ceptors [3]. In untreated cells, the ratio of sequestered to total 
binding sites (20%) was identical for the wild-type and the μ8/ 
T[i3+Cter]A receptors (Table 3). As reported for μ- and δ-
opioid receptors [3,8,12-16], sequestration and/or internaliza-
tion of the wild-type μ-opioid receptor was rapidly (30 min) 
induced upon activation by DAGO and etorphine. Surpris-
ingly, μ receptors were also down-regulated after such a short 
exposition period to DAGO or etorphine. This is markedly 
distinct from the more slowly developing process (several 
hours) occurring for ß-adrenergic receptors but has already 
been described for the μ-opioid receptor [14]. After longer 
periods (24 h) in the presence of DAGO or etorphine, the 
total number of binding sites was still reduced by about 
50% but the ratio of sequestered sites returned to control 
values (Table 3). Neither sequestration nor down-regulation 
was observed with morphine which rather seemed to induce a 
slight diminution of DAGO inaccessible sites. 
In contrast, no sequestration or down-regulation was ob-
served with the μδ/Τ[ί3+ΟεΓ]Α receptor which was instead 
up-regulated after 24 h of treatment with either agonist (Table 
3). Moreover, the ratio of sequestered mutant receptors 
seemed to be decreased upon stimulation by morphine and 
this was accompanied by a much higher extent of receptor 
up-regulation as compared to DAGO and etorphine. 
4. Discussion 
4.1. Ser and Thr residues in the third cytoplasmic loop and 
C-terminus are involved in coupling of the μ-opioid 
receptor to G-proteins 
Wild-type and μδ/Τ[ί3+ΟεΓ]Α receptors had similar appar-
ent affinities for the antagonist [3H]diprenorphine and for the 
agonists DAGO, morphine and etorphine. The occurrence in 
the mutant receptor of a single affinity state for agonists, 
insensitive to Gpp(NH)p, did not reflect uncoupling from 
G-proteins since both receptors inhibited FS-induced cAMP 
accumulation with identical EC50 values. Moreover, in the 
wild-type μ receptor K\s at the low affinity state for agonists 
were in the same range as EC50 values, suggesting that even in 
this receptor the low affinity state for agonists substantially 
contributed to inhibition of adenylyl cyclase. As observed here 
for the wild-type and mutant μ receptors, others have re-
ported on the existence of muscarinic [17] and 5-hydroxytrypt-
amine [18,19] receptor agonists with a single affinity binding 
site insensitive to GTP analogs. As further supported in sev-
eral systems by the existence of partial agonists with high 
binding affinity, this suggests that agonist affinity and efficacy 
are not directly related. Coupling of receptors to slow GDP-
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GTP exchanging Go and Gq proteins, which mediate opioid 
as well as muscarinic and serotoninergic signals, may explain 
the lack of effect of Gpp(NH)p on agonist affinity. 
The μ8/Τ[ί3+ΟΐβΓ]Α receptor still had the ability to undergo 
isomerization to active conformations but the effects exerted 
by agonists on this process and/or on interactions of active 
conformations with G-proteins were certainly altered since the 
maximal inhibitory effects on adenylyl cyclase activity were 
lower for mutant than for wild-type receptors. Opioid recep-
tors which are highly promiscuous in terms of coupling to G-
proteins certainly exist under several conformations of differ-
ent affinity for individual G-protein isoforms. The lower po-
tency of the μ8/Τ[ί3+€ΐβΓ]Α receptor to inhibit adenylyl cy-
clase and the occurrence of a single affinity site for agonists 
may thus suggest that the order of affinity of the mutant 
receptor for the G-proteins normally interacting with μ recep-
tors was modified, either because the mutated Ser and Thr 
residues directly interact with specific G-proteins or because 
they stabilize particular agonist-bound receptor conforma-
tions. 
4.2. Long-term exposure to agonists of μ-opioid receptors 
expressed in CHO-K1 cells does not induce receptor 
desensitization but promotes adenylyl cyclase 
superactivation 
Both the μ and μ8/Τ[ί3+ΟΐεΓ]Α receptors chronically 
treated with DAGO, morphine or etorphine were able to 
modulate adenylyl cyclase activity upon stimulation by the 
corresponding agonist in an essentially similar fashion as be-
fore treatment. The decreased overshoot obtained with the μ8/ 
T[i3+Cter]A mutant may reflect the lower potency of the ag-
onists at this receptor since adenylyl cyclase superactivation is 
mediated by βγ subunits of G-proteins and is thus propor-
tional to the degree of receptor stimulation [20]. Thus, the 
limited desensitization observed for morphine and etorphine, 
and the adenylyl cyclase superactivation certainly did not in-
volve receptor phosphorylation in the third cytoplasmic loop 
or in the carboxy-terminal tail. The phosphorylation sites 
present in the first and second cytoplasmic loops may, how-
ever, be implicated in such processes. Alternatively, this may 
be due to coupling of the activated receptors to different G-
protein isoforms. 
The present results on the long-term effects of agonists on 
the μ-opioid receptor expressed in CHO-K1 cells agree with 
those of Avidor-Reiss et al. [9] but differ from others in the 
same cell line [14] or in 7315c pituitary [12] and neuro2 cells 
[8], where decreased EC50 values for morphine and DAGO 
were observed concomitantly with diminished maximal poten-
cies. As for other receptors [21,22], such variations might be 
explained by tissue specificity of the desensitization process. 
Nevertheless, our results contradict those of Blake and collab-
orators [10] and suggest that the apparent desensitization and 
lack of rebound effect observed after chronic etorphine are 
best explained by receptor occupancy by this slowly dissociat-
ing agonist. 
Adaptive changes in μ-opioid receptor responsiveness may 
also depend on experimental conditions since we and Avidor-
Reiss et al. used whole cells whereas others used membrane 
fractions [12,14]. It is possible that one of the many proteins 
(GRKs, arrestins, phosducins, recoverins) which modulate 
signaling by G-proteins and coupled receptors [1] may be 
silenced in some cell types but that this necessitates an intact 
cellular machinery and/or particular experimental conditions. 
For example, the myristoylated brain membrane protein neu-
rocalcin inhibits phosphorylation and desensitization of rho-
dopsin [23] but requires the presence of Ca2+ for proper in-
teractions with tubulin and rhodopsin kinase [23]. 
4.3. Ser and Thr residues in the third cytoplasmic loop and 
C-terminus are involved in agonist-regulated trafficking 
of the μ-opioid receptor 
Our results on μ-opioid receptor sequestration and down-
regulation suggest a direct relationship between these two 
processes. Indeed, sequestration of wild-type μ-receptors oc-
curred rapidly and concomitant with down-regulation upon 
exposure to DAGO and etorphine. Moreover, sequestration 
of μ receptors was not stimulated by morphine [3,15] but 
rather reduced, and this correlated with an absence of 
down-regulation. Furthermore, the ratio of sequestered μδ/ 
T[i3+Cter]A receptors was much lower upon morphine treat-
ment, as compared to DAGO and etorphine, and was paral-
leled by a higher up-regulation of receptor number. 
A recent model for trafficking of the ß2-adrenergic receptor 
postulates that receptors are dynamically exchanged between 
the plasma membrane and endosomes and from there are 
either recycled to the cell surface or directed towards lyso-
somes and degraded [24]. Agonists may modulate the cellular 
density and the membrane ratio of receptors by individually 
affecting each of the steps involved in trafficking: (i) seques-
tration into endosomes, (ii) recycling to the membrane or (iii) 
internalization into lysosomes. The agonist-bound ß2-adrener-
gic receptor is rapidly sequestered and predominantly recycled 
to the membrane, since receptor desensitization decreases G-
protein coupling and agonist binding, two properties which 
are required for down-regulation (reviewed in [25]). 
The absence of desensitization of the μ-opioid receptor ex-
pressed in CHO cells may thus favor the lysosome pathway 
resulting in rapid down-regulation. The receptor conforma-
tion^) involved in the sequestration/recycling/degradation 
pathways could be largely disfavored in the μ8/Τ[ί3+ΟβΓ]Α 
mutant, resulting in a degradation rate substantially lower 
than that of synthesis, eventually leading to receptor up-reg-
ulation. This may occur as a consequence of a limited receptor 
supply to the lysosomal compartment, arising either from an 
impaired ability of the μ8/Τ[ί3+ΟΐβΓ]Α receptor to sequester 
into endosomes or from an increased rate of recycling due to 
the unphosphorylated state of this receptor. This latter possi-
bility is suggested by studies on the ß2-adrenergic receptor 
demonstrating that receptors are dephosphorylated before 
being recycled to the plasma [25]. The unique property of 
morphine suggests that upon binding to μ or μδ/Τ[ί3+€ίβΓ]Α 
receptors, this agonist may promote a receptor form of lower 
propensity to sequestration and/or degradation. 
Previous studies on G-protein-coupled receptors, including 
the δ-opioid receptor [16], have demonstrated a role for Ser-
and Thr-rich domains in the internalization/down-regulation 
processes [25]. From these and our studies, it remains unclear 
whether the role of these Ser and Thr residues relies on their 
chemical characteristics or on their phosphorylation. The 
present observations suggest that the Ser and Thr residues 
of the third cytoplasmic and C-terminal domains of the μ 
receptor may be implicated in receptor/G-protein interaction 
and/or in the conformational flexibility of the intracellular 
domains. Mutations such as those studied here in the μδ/ 
R. Capeyrou et al.lFEBS Letters 415 (1997) 200-205 205 
T[i3+Cter]A receptor may thus affect one of the many steps 
involved in the intricate and coordinately regulated pathways 
of receptor signaling and trafficking. 
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